Summary
US8693671021 Chart
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
Sutro Biopharma Inc. Dividends
Sutro Biopharma Inc. Earnings
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
Sutro Biopharma Inc. (US8693671021) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sutro Biopharma Inc. ever had a stock split?
Sutro Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ms. Jane Chung R.Ph. CEO | XSTU Exchange | US8693671021 ISIN |
| US Country | 269 Employees | - Last Dividend | - Last Split | 27 Sep 2018 IPO Date |
Overview
Sutro Biopharma, Inc. stands as a pivotal clinical-stage oncology company, distinguished by its innovative approach towards treating cancer. Established in 2003 and originally named Fundamental Applied Biology, Inc., the company has since evolved, situating its headquarters in South San Francisco, California. Sutro Biopharma is at the forefront of developing site-specific and novel-format antibody drug conjugates (ADC) through its proprietary cell-free protein synthesis platforms, XpressCF, and XpressCF+. These advancements are tailored to address the unmet needs within oncology, focusing on delivering cutting-edge treatments for patients battling cancer. Additionally, Sutro Biopharma actively engages in collaboration and license agreements with esteemed entities like Merck, Celgene Corporation, EMD Serono, and Astellas Pharma Inc., aiming to expand the horizons of its ADC technologies across various cancer targets and autoimmune disorders.
Products and Services
STRO-001: An innovative antibody drug conjugate (ADC) specifically targeting CD74, a cancer-associated antigen. Currently in Phase 1 clinical trials, STRO-001 is designed for patients suffering from multiple myeloma and non-Hodgkin lymphoma. This treatment exemplifies Sutro Biopharma's commitment to addressing cancers with a high unmet medical need through targeted therapy.
STRO-002: This ADC is directed against folate receptor-alpha, a therapeutic target associated with ovarian and endometrial cancers. STRO-002 is in Phase 1 clinical trials, representing a strategic focus on gynecological malignancies by engaging in cutting-edge research to provide novel treatment options for patients.
STRO-003: A pre-clinical product candidate, STRO-003 is an ADC targeting the anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential applications in the treatment of solid tumors. This initiative underscores Sutro Biopharma’s dedication to expanding its ADC portfolio into broader oncology indications.
Contact Information
